FDA Approves ROXYBOND — Protega Pharmaceuticals Inc

Protega Pharmaceuticals Inc. has received FDA approval for Roxycbond (oxycodone hydrochloride), a crucial strategic addition for the company intended to bolster its market portfolio. This high-demand oral formulation is expected to significantly impact market share by providing stakeholders with a cost-effective alternative to established brand opioids.